Arudchandran R, Brown M J, Peirce M J, Song J S, Zhang J, Siraganian R P, Blank U, Rivera J
Section on Chemical Immunology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Exp Med. 2000 Jan 3;191(1):47-60. doi: 10.1084/jem.191.1.47.
Vav is a hematopoietic cell-specific guanine nucleotide exchange factor (GEF) whose activation is mediated by receptor engagement. The relationship of Vav localization to its function is presently unclear. We found that Vav redistributes to the plasma membrane in response to Fcin receptor I (FcinRI) engagement. The redistribution of Vav was mediated by its Src homology 2 (SH2) domain and required Syk activity. The FcinRI and Vav were found to colocalize and were recruited to glycosphingolipid-enriched microdomains (GEMs). The scaffold protein, linker for activation of T cells (LAT), and Rac1 (a target of Vav activity) were constitutively present in GEMs. Expression of an SH2 domain-containing COOH-terminal fragment of Vav inhibited Vav phosphorylation and movement to the GEMs but had no effect on the tyrosine phosphorylation of the adaptor protein, SLP-76 (SH2 domain-containing leukocyte protein of 76 kD), and LAT. However, assembly of the multiprotein complex containing these proteins was inhibited. In addition, FcinRI-dependent activation of c-Jun NH(2)-terminal kinase 1 (JNK1) was also inhibited. Thus, Vav localization to the plasma membrane is mediated by its SH2 domain and may serve to regulate downstream effectors like JNK1.
Vav是一种造血细胞特异性鸟嘌呤核苷酸交换因子(GEF),其激活由受体结合介导。目前尚不清楚Vav的定位与其功能之间的关系。我们发现,Vav会响应Fcγ受体I(FcγRI)的结合而重新分布到质膜上。Vav的重新分布由其Src同源2(SH2)结构域介导,并且需要Syk活性。研究发现FcγRI和Vav共定位,并被募集到富含糖鞘脂的微结构域(GEMs)中。支架蛋白、T细胞激活连接蛋白(LAT)和Rac1(Vav活性的一个靶点)在GEMs中组成性存在。Vav含SH2结构域的COOH末端片段的表达抑制了Vav的磷酸化及其向GEMs的移动,但对衔接蛋白SLP-76(含76kD SH2结构域的白细胞蛋白)和LAT的酪氨酸磷酸化没有影响。然而,包含这些蛋白的多蛋白复合物的组装受到了抑制。此外,FcγRI依赖的c-Jun氨基末端激酶1(JNK1)的激活也受到了抑制。因此,Vav向质膜的定位由其SH2结构域介导,可能用于调节像JNK1这样的下游效应器。